{"disease":{"id":"local-cancer","name":"local cancer"},"drugs":{"marketed":[{"drug_id":"sotorasib","indication_name":"KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lumakras","generic_name":"SOTORASIB","company_name":"Amgen","drug_phase":"marketed","molecular_target":"GTPase KRas","drug_class":"","quality_score":65,"revenue":"300","mechanism":"Lumakras works by covalently binding to the KRAS G12C mutation, thereby blocking the protein's ability to promote cancer cell growth."},{"drug_id":"adagrasib","indication_name":"KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Krazati","generic_name":"ADAGRASIB","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"GTPase KRas","drug_class":"","quality_score":66,"revenue":"205","mechanism":"Krazati works by binding to and inhibiting the GTPase activity of the KRAS G12C protein, preventing it from sending signals that promote cancer cell growth."},{"drug_id":"repotrectinib","indication_name":"Locally advanced or metastatic ROS1-positive non-small cell lung cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Augtyro","generic_name":"REPOTRECTINIB","company_name":"Bristol","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":60,"revenue":"200","mechanism":"Augtyro blocks the activity of ROS1 and NTRK kinases, which are abnormal proteins that help cancer cells grow and spread."},{"drug_id":"talzenna","indication_name":"BRCA-mutated (g BRCA m) HER2-negative Locally Advanced or Metastatic Breast Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Talzenna","generic_name":"Talazoparib Tosylate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"PARP1 and PARP2 enzymes","drug_class":"PARP inhibitor","quality_score":75,"revenue":"182","mechanism":"PARP1/PARP2 inhibitor causing DNA damage, decreased proliferation, and apoptosis in BRCA-mutated cancers."},{"drug_id":"neo-bladder-construct","indication_name":"BRAF V600E Mutation-Positive Locally Advanced or Metastatic Anaplastic Thyroid Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"\"Neo-Bladder\" Construct","company_name":"Wake Forest University Health Sciences","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":29,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl3301589","indication_name":"Locally Advanced or Metastatic Urothelial Cancer (Combination Therapy)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ENFORTUMAB VEDOTIN","company_name":"","drug_phase":"marketed","molecular_target":"Nectin-4","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Enfortumab vedotin-ejfv binds to Nectin-4 on cancer cells, internalizes, releases MMAE, disrupting microtubules and causing cell death."},{"drug_id":"chembl-chembl3301589","indication_name":"Locally Advanced or Metastatic Urothelial Cancer (Single Agent)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ENFORTUMAB VEDOTIN","company_name":"","drug_phase":"marketed","molecular_target":"Nectin-4","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Enfortumab vedotin-ejfv binds to Nectin-4 on cancer cells, internalizes, releases MMAE, disrupting microtubules and causing cell death."},{"drug_id":"sulfur-colloid","indication_name":"Lymph node localization in breast cancer or melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Sulfur Colloid","company_name":"University of California, San Diego","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":35,"revenue":null,"mechanism":"Technetium Tc 99m Sulfur Colloid is used for imaging by entering lymphatic capillaries, mixing with peritoneal fluid, or being taken up by the reticuloendothelial system."},{"drug_id":"sulfur-colloid","indication_name":"Lymph node localization in breast cancer or melanoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Sulfur Colloid","company_name":"University of California, San Diego","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":35,"revenue":null,"mechanism":"Technetium Tc 99m Sulfur Colloid is used for imaging by entering lymphatic capillaries, mixing with peritoneal fluid, or being taken up by the reticuloendothelial system."},{"drug_id":"ensartinib","indication_name":"ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ensacove","generic_name":"ENSARTINIB","company_name":"Xcovery","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":49,"revenue":null,"mechanism":"Ensartinib works by inhibiting a specific protein that drives the growth of cancer cells."},{"drug_id":"deruxtecan","indication_name":"Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Datroway","generic_name":"DERUXTECAN","company_name":"Daiichi Sankyo","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":44,"revenue":null,"mechanism":"Deruxtecan works by binding to and inhibiting the growth of cancer cells."},{"drug_id":"telisotuzumab","indication_name":"locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Emrelis","generic_name":"TELISOTUZUMAB","company_name":"Abbvie Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Emrelis binds to the c-Met protein on cancer cells, blocking its growth-promoting signals."},{"drug_id":"palbociclib","indication_name":"Treatment of adult patients with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy, in combination with inavolisib and fulvestrant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib","generic_name":"palbociclib","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cyclin-dependent kinases 4 and 6 (CDK4/6)","drug_class":"CDK4/6 inhibitor","quality_score":70,"revenue":null,"mechanism":"Palbociclib inhibits CDK4/6 to block G1/S cell cycle progression in ER-positive breast cancer."},{"drug_id":"taletrectinib","indication_name":"locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ibtrozi","generic_name":"TALETRECTINIB","company_name":"Nuvation","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Ibtrozi works by blocking the ROS1 protein, which is a genetic mutation found in some lung cancer cells."},{"drug_id":"trametinib","indication_name":"Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mekinist","generic_name":"trametinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Dual specificity mitogen-activated protein kinase kinase 2","drug_class":"Kinase Inhibitor","quality_score":71,"revenue":null,"mechanism":"Mekinist works by blocking a specific enzyme called BRAF V600E, which is involved in the growth and spread of cancer cells."},{"drug_id":"capecitabine","indication_name":"Perioperative treatment of locally advanced rectal cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeloda","generic_name":"capecitabine","company_name":"Cheplapharm","drug_phase":"marketed","molecular_target":"Thymidylate synthase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":67,"revenue":null,"mechanism":"Xeloda works by inhibiting the enzyme thymidylate synthase, which is necessary for DNA synthesis in cancer cells."},{"drug_id":"chembl-chembl4650215","indication_name":"endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Itovebi","generic_name":"INAVOLISIB","company_name":"Genentech Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":"Itovebi works by blocking a specific enzyme called PIK3CA, which is involved in the growth and spread of cancer cells."},{"drug_id":"ixabepilone","indication_name":"Metastatic or locally advanced breast cancer with capecitabine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ixempra Kit","generic_name":"IXABEPILONE","company_name":"R-Pharm Us Llc","drug_phase":"marketed","molecular_target":"Apoptosis regulator Bcl-2","drug_class":"Microtubule Inhibitor","quality_score":64,"revenue":null,"mechanism":"Ixempra Kit works by disrupting cell division, preventing cancer cells from growing and multiplying."},{"drug_id":"ixabepilone","indication_name":"Metastatic or locally advanced breast cancer as a single agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ixempra Kit","generic_name":"IXABEPILONE","company_name":"R-Pharm Us Llc","drug_phase":"marketed","molecular_target":"Apoptosis regulator Bcl-2","drug_class":"Microtubule Inhibitor","quality_score":64,"revenue":null,"mechanism":"Ixempra Kit works by disrupting cell division, preventing cancer cells from growing and multiplying."},{"drug_id":"chembl-chembl2103875","indication_name":"BRAF V600E Mutation-Positive Locally Advanced or Metastatic Anaplastic Thyroid Cancer (Combination with Dabrafenib)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TRAMETINIB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":5,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":20,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05217381","title":"Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status","phase":"","overall_status":"COMPLETED","enrollment_count":18533,"lead_sponsor_name":"MedSIR","has_results":false},{"nct_id":"NCT07351708","title":"Development and Validation of a Post-operative Risk Of Local Recurrence Model Integrating Serology and Evalution (PROMISE) in Local Advanced Rectal Cancer Receiving Neoadjuvant Therapy: a Multicenter Study","phase":"","overall_status":"COMPLETED","enrollment_count":2315,"lead_sponsor_name":"Cai Zerong","has_results":false},{"nct_id":"NCT05957068","title":"Breast Cancer Exercise Intervention Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":2156,"lead_sponsor_name":"National Cancer Centre, Singapore","has_results":false},{"nct_id":"NCT07401199","title":"Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Qun Zhao","has_results":false},{"nct_id":"NCT05378087","title":"Comparing the Efficacy of Surgery Staging and Image Staging of Locally Advanced Cervical Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":1956,"lead_sponsor_name":"Chongqing University Cancer Hospital","has_results":false},{"nct_id":"NCT05339568","title":"Patient's Whole Process Follow-up Management(HOPE-1)","phase":"","overall_status":"RECRUITING","enrollment_count":1268,"lead_sponsor_name":"Qianfoshan Hospital","has_results":false},{"nct_id":"NCT03682068","title":"Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1246,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06979817","title":"Machine Learning Model Guided by TLS Predicts Survival and Immune Features in Gastric Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":1200,"lead_sponsor_name":"Qun Zhao","has_results":false},{"nct_id":"NCT06783491","title":"Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":1083,"lead_sponsor_name":"Maimónides Biomedical Research Institute of Córdoba","has_results":false},{"nct_id":"NCT07343349","title":"Addition of Focal Boost to Primary Radiotherapy for Prostate Cancer in 12 or 20 Fractions","phase":"NA","overall_status":"RECRUITING","enrollment_count":1016,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT04948762","title":"A Contemporary Review of Surgical Approaches in Pelvic Exenterative Surgery","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"St Vincent's University Hospital, Ireland","has_results":false},{"nct_id":"NCT04546009","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":992,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT05296798","title":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":922,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT07164885","title":"RAPART in Locally Advanced Non-small Cell Lung Cancer Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":911,"lead_sponsor_name":"Capital Medical University","has_results":false},{"nct_id":"NCT05406999","title":"Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":900,"lead_sponsor_name":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","has_results":false},{"nct_id":"NCT04862663","title":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":895,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT00911170","title":"PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":847,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT04305496","title":"Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT06079671","title":"Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04789980","title":"Good Choice of pALliative Chemotherapy to Patient With Pancreatic Cancer ; GemcitAbine Therapy vs FOLFORINOX therapY","phase":"","overall_status":"COMPLETED","enrollment_count":799,"lead_sponsor_name":"Boryung Pharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT05610163","title":"Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":783,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT06028724","title":"A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)","phase":"","overall_status":"RECRUITING","enrollment_count":782,"lead_sponsor_name":"Centro di Riferimento Oncologico - Aviano","has_results":false},{"nct_id":"NCT03830866","title":"Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":770,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT03244384","title":"Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":739,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04527991","title":"Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":712,"lead_sponsor_name":"Gilead Sciences","has_results":false},{"nct_id":"NCT02296125","title":"AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":674,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT04143230","title":"Identification of In-hospital Patients in Need of Palliative Care Using a New Simplified Screening Tool","phase":"NA","overall_status":"COMPLETED","enrollment_count":660,"lead_sponsor_name":"A.O.U. Città della Salute e della Scienza","has_results":false},{"nct_id":"NCT05356741","title":"To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":645,"lead_sponsor_name":"Vir Biotechnology, Inc.","has_results":false},{"nct_id":"NCT01880359","title":"AF CRT +/- Nimorazole in HNSCC","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":640,"lead_sponsor_name":"European Organisation for Research and Treatment of Cancer - EORTC","has_results":false},{"nct_id":"NCT05673590","title":"Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":612,"lead_sponsor_name":"Beijing Biostar Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT01526928","title":"Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":612,"lead_sponsor_name":"Clovis Oncology, Inc.","has_results":true},{"nct_id":"NCT05646511","title":"TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":608,"lead_sponsor_name":"National Cancer Center Hospital East","has_results":false},{"nct_id":"NCT06733350","title":"Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT06716593","title":"Trajectory of Body Composition Identifies LAGC with Cachexia Following NACT","phase":"","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"Chang-Ming Huang, Prof.","has_results":false},{"nct_id":"NCT06873191","title":"A Study to Learn More About Tukysa Once it is Out in the Korean Market","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT05919264","title":"FOG-001 in Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":595,"lead_sponsor_name":"Parabilis Medicines, Inc.","has_results":false},{"nct_id":"NCT06235164","title":"The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":585,"lead_sponsor_name":"Fujian Medical University","has_results":false},{"nct_id":"NCT03504397","title":"A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":565,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT03961373","title":"Standard Versus Super-extended Lymphadenectomy After Neo-adjuvant Chemotherapy for Gastric Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":539,"lead_sponsor_name":"University of Siena","has_results":false},{"nct_id":"NCT03238885","title":"Predicting Pathological Complete Response of Rectal Cancer With Magnetic Resonance(MR) Radiomics","phase":"","overall_status":"COMPLETED","enrollment_count":538,"lead_sponsor_name":"Sun Ying-Shi","has_results":false},{"nct_id":"NCT06747338","title":"A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":520,"lead_sponsor_name":"Shanghai JMT-Bio Inc.","has_results":false},{"nct_id":"NCT05653453","title":"Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":512,"lead_sponsor_name":"Jiangsu Healthy Life Innovation Medical Technology Co., Ltd","has_results":false},{"nct_id":"NCT05172518","title":"Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":512,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT01933932","title":"Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":510,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT03653507","title":"A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":507,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT06901531","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT06114420","title":"Surgical Treatment and Molecular Marker Exploration of Locally Recurrent Colorectal Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT06075524","title":"Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06759480","title":"Study of Laparoscopic Radical Hysterectomy Based on Space Anatomy in Patients With IB3 and IIA2 Cervical Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"International Peace Maternity and Child Health Hospital","has_results":false},{"nct_id":"NCT03149978","title":"Tumor Response Prediction in Neoadjuvant Chemoradiation of Locally Advanced Rectal Cancer Using Metabonomics Analysis","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Zhu Ji","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}